CA2266684A1 - Use of antibodies to cd45r leukocyte antigens for immunomodulation - Google Patents

Use of antibodies to cd45r leukocyte antigens for immunomodulation Download PDF

Info

Publication number
CA2266684A1
CA2266684A1 CA002266684A CA2266684A CA2266684A1 CA 2266684 A1 CA2266684 A1 CA 2266684A1 CA 002266684 A CA002266684 A CA 002266684A CA 2266684 A CA2266684 A CA 2266684A CA 2266684 A1 CA2266684 A1 CA 2266684A1
Authority
CA
Canada
Prior art keywords
antibody
cell
tissue
organ
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002266684A
Other languages
English (en)
French (fr)
Inventor
Andrew I. Lazarovits
Sibrand Poppema
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alimmune LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2266684A1 publication Critical patent/CA2266684A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002266684A 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation Abandoned CA2266684A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/715,342 US6106834A (en) 1993-06-02 1996-09-18 Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US08/715,342 1996-09-18
PCT/US1997/016321 WO1998011918A1 (en) 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation

Publications (1)

Publication Number Publication Date
CA2266684A1 true CA2266684A1 (en) 1998-03-26

Family

ID=24873646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266684A Abandoned CA2266684A1 (en) 1996-09-18 1997-09-17 Use of antibodies to cd45r leukocyte antigens for immunomodulation

Country Status (8)

Country Link
US (3) US6106834A (https=)
EP (1) EP0939652B1 (https=)
JP (1) JP2001501607A (https=)
AT (1) ATE301471T1 (https=)
CA (1) CA2266684A1 (https=)
DE (1) DE69733960T2 (https=)
ES (1) ES2247638T3 (https=)
WO (1) WO1998011918A1 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7014998B2 (en) 2000-09-30 2006-03-21 Yale University Screening immunomodulatory agents by CTLA-4 upregulation
US20050069538A1 (en) * 2003-09-18 2005-03-31 Gregorio Aversa Therapeutic binding molecules
GB0103389D0 (en) * 2001-02-12 2001-03-28 Novartis Ag Organic compounds
AU2002351204B2 (en) * 2001-12-03 2008-07-10 Abgenix, Inc. Anti-CD45RB antibodies for use in treating autoimmune disease and transplant rejection
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
WO2003061695A1 (en) * 2002-01-17 2003-07-31 Amgen Inc. Methods of regulating cytokine receptor signaling
AU2003279657A1 (en) * 2002-07-01 2004-01-19 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
US20040146503A1 (en) * 2002-08-28 2004-07-29 Tesi Raymond J. Methods and compositions for inducing stable immune tolerance
US20040047858A1 (en) * 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
WO2005018668A1 (en) * 2003-08-25 2005-03-03 Pangenetics B.V. Method of inducing immune tolerance
HRP20100334T1 (hr) * 2003-09-18 2010-07-31 Novartis Ag Terapeutska humanizirana antitijela protiv cd45-izoforma
WO2007087453A2 (en) * 2006-01-27 2007-08-02 Cellerant Therapeutics, Inc. Compositions and methods for treating haematological proliferative disorders
EP2029729A2 (en) * 2006-05-31 2009-03-04 Genzyme Corporation Methods of using anti-thymocyte globulin and related agents
ES2526548T3 (es) 2006-08-18 2015-01-13 Argos Therapeutics, Inc. Uso de CD83 en terapias de combinación
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US9045556B2 (en) 2007-02-07 2015-06-02 Nec Corporation Therapeutic agent for cancer
WO2013021784A1 (ja) * 2011-08-10 2013-02-14 ナパジェン ファーマ，インコーポレテッド 免疫寛容誘導剤
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
ES2653639T3 (es) 2011-02-28 2018-02-08 Napajen Pharma, Inc. Complejo ácido nucleico-polisacárido
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
EP3174902B1 (en) 2014-08-01 2019-04-17 Institut National de la Sante et de la Recherche Medicale (INSERM) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
EP3355937A4 (en) 2015-09-28 2019-04-17 Regents of the University of Minnesota CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY
GB201521391D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
GB201521393D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
BR112018076306A2 (pt) 2016-06-17 2019-03-26 Magenta Therapeutics, Inc. composições e métodos para a supressão de células cd117+
CA3042683A1 (en) 2016-11-07 2018-05-11 Coimmune, Inc. Bispecific antibodies that modulate tlr-4 signaling and uses thereof
MX395639B (es) 2017-01-20 2025-03-25 Heidelberg Pharma Res Gmbh Composiciones y métodos para el agotamiento de células cd137+.
EP3514541A1 (de) * 2018-01-17 2019-07-24 Siemens Healthcare Diagnostics Products GmbH Verfahren zur quantitativen bestimmung eines therapeutischen tnf-alpha inhibitors
CA3128518A1 (en) * 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
CN111707833A (zh) * 2020-06-19 2020-09-25 徐州医科大学 小鼠血管内外淋巴细胞识别的方法及其应用
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
WO2022196719A1 (ja) 2021-03-17 2022-09-22 第一三共株式会社 抗アセチルコリン受容体自己抗体に対するキメラ受容体をコードする遺伝子
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
WO2023201339A1 (en) 2022-04-15 2023-10-19 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
US20240261405A1 (en) 2022-06-08 2024-08-08 Kyverna Therapeutics, Inc. Methods and compositions for treating autoimmune disease
CN120554513B (zh) * 2025-07-28 2025-11-21 杭州华大生命科学研究院 一种抗cd45抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626507A (en) * 1980-09-25 1986-12-02 The Salk Institute For Biological Studies Hybridomas producing monoclonal antibodies specific for a human cell surface glycoprotein
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
FI921746A0 (fi) * 1989-10-20 1992-04-16 Lynxvale Ltd Material och metoder foer behandling av fraemmande vaevnad.
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DE69226871T3 (de) * 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
GB9323542D0 (en) * 1993-11-15 1994-01-05 Univ Alberta Lymphocyte marker specific for corhn's disease
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US6174710B1 (en) 1994-08-09 2001-01-16 Pfizer Inc. Spirolaxine derivatives for treating gastrobuodenal diseases

Also Published As

Publication number Publication date
US6106834A (en) 2000-08-22
ES2247638T3 (es) 2006-03-01
EP0939652B1 (en) 2005-08-10
DE69733960D1 (de) 2005-09-15
JP2001501607A (ja) 2001-02-06
ATE301471T1 (de) 2005-08-15
US20020168362A1 (en) 2002-11-14
US6379668B1 (en) 2002-04-30
US7160987B2 (en) 2007-01-09
EP0939652A1 (en) 1999-09-08
DE69733960T2 (de) 2006-05-24
WO1998011918A1 (en) 1998-03-26

Similar Documents

Publication Publication Date Title
CA2266684A1 (en) Use of antibodies to cd45r leukocyte antigens for immunomodulation
AU711605B2 (en) CD45RB binding compounds for the prevention of transplant rejection
EP1421191B1 (en) Humanised antibodies specific for both CD45RB and CD45RO
US5635156A (en) Non-lethal methods for conditioning a recipient for bone marrow transplantation
JPS649999B2 (https=)
PL170321B1 (pl) Sposób wytwarzania nowej czasteczki wiazacej CD25 PL PL PL PL PL PL
CA2163344A1 (en) Humanised antibodies
JPS6362520B2 (https=)
EP1664122B1 (en) Therapeutic humanised antibodies against cd45 isoforms
US5514364A (en) Non-lethal methods for conditioning a recipient for bone marrow transplantation
US6994976B1 (en) Tr3-specific binding agents and methods for their use
US6433148B1 (en) Monoclonal anti-idiotypic antibodies (AB2) and their uses
US20040052780A1 (en) Immunosuppresants
EP0303463B1 (en) Method to control leukocyte extravasation
US8900586B2 (en) Antibody that binds domain 2 of ICAM-1 and methods of treatment
KR100204733B1 (ko) 인체 4-1비비 분자에 특이성이 있고 면역억제 효과를 갖는 모노클로날 항체
Chatenoud et al. OKT3 in allogeneic transplantation: clinical efficacy, mode of action, and side effects
JP2004149507A (ja) 免疫抑制剤
FI75433C (fi) Diagnostiskt foerfarande, i vilket anvaends en specifik monoklonal antikropp till maensklig protymocyt antigen och i foerfarandet anvaendbar komposition.
HK1091844B (en) Therapeutic humanised antibodies against cd45 isoforms
HRP940823A2 (en) Hybrid cell line for producing monoclonal antibody to a human early thymocite antigen, antibody and method of preparation of this antibody

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued